Home » Pharmacology » 7-TM Receptors » Acetylcholine Muscarinic Receptors » Oxotremorine M

Oxotremorine M

Cat No. 1067

Price and Availability

For Oxotremorine M pricing & availability please select your country from the drop down menu:
Submit

Chemical Name: N,N,N-Trimethyl-4-(2-oxo-1-pyrolidinyl)-2-butyn-1-ammon ium iodide

Biological Activity

Muscarinic receptor agonist.

Technical Data

M.Wt:

322.19

Formula:

C₁₁H₁₉IN₂O

Solubility:

Soluble to 100 mM in water

Purity:

>98 %

Storage:

Desiccate at -20°C

CAS No:

[63939-65-1]

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis and MSDS.

Resources

Certificate of Analysis / MSDS

Certificate of Analysis: View current batch

For specific/earlier batch please select:

Material Safety Data Sheet: View current batch

For specific/earlier batch please select:

References

Birdsall et al (1978) The binding of agonists to brain muscarinic receptors. Mol.Pharmacol. 14 723. Kukkonen et al (1996) Functional properties of muscarinic receptor subtypes Hm1, Hm3 and Hm5 expressed in Sf9 cells using the baculovirus expression system. J.Pharmacol.Exp.Ther. 279 593

If you know of a useful citation for this product please let us know.

View Related Products by Target

Acetylcholine Muscarinic Receptors

Keywords: Oxotremorine M, Muscarinic, agonists, Receptors, Acetylcholine, ACh, OxotremorineM

Buy Now / Print Quote

Find multiple products by catalog number

Print Quote Facility

Order via your purchasing department

It's now even easier to place orders via your purchasing department.

Simply add a product to your cart & click on the "Print Quote" button.

GPCRs and Signalling Networks

Written by M.J. Marinissen

'G-Protein-coupled Receptors and Signalling Networks' summarizes the intricate network of intracellular signalling pathways involved in GPCR function.

7-TM Receptor Signalling

Written by T. Kenakin et al

'Seven Transmembrane Receptor Signalling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy